Advisory Opinion 21-16
Regarding a pharmaceutical manufacturer’s arrangement to provide up to a specified number of trial units of a long-acting antipsychotic drug to certain hospitals for inpatient use.
This is a computer translation of the original webpage. It is provided for general information only and should not be regarded as complete nor accurate. |